Getting your player ready...
WASHINGTON — The Food and Drug Administration has taken the unprecedented step of acknowledging it buckled to “extreme” pressure from Capitol Hill in its approval of a knee-repair device last year.
While FDA officials call the situation an anomaly, experts said Friday there is nothing to stop similar lobbying from influencing future decisions.
In a sweeping critique Thursday, FDA leadership said the agency failed to protect its scientists from outside pressure after they twice rejected ReGen Biologics’ Menaflex device.
